Despite higher tumor antigen expression in squamous cell lung cancer, T cell responses to peptide antigens were significantly weaker than in adenocarcinoma patients, revealing subtype-specific immune differences.
Paradox: more antigens, weaker responseSCC expressed more tumor antigens but had significantly lower T cell responsiveness than adenocarcinoma patients
What the researchers found
Squamous cell lung cancer patients showed significantly weaker T cell responses to tumor peptide antigens than adenocarcinoma patients despite higher antigen expression, indicating subtype-specific immune suppression.
Why it matters
Understanding why different lung cancer subtypes respond differently to immune stimulation is critical for designing effective peptide-based cancer vaccines and immunotherapies.
The numbers in context
12 TAAs tested; 6 cell lines; 52 primary tumors; 32 patients; 4 of 6 cell lines suitable; Phase I trial NCT02470468
How the study worked
Observational study analyzing tumor antigen expression in 6 cell lines and 52 primary tumors, plus peptide-specific T cell stimulation assays in 32 NSCLC patient blood samples.
Who was studied
NSCLC patients (adenocarcinoma and squamous cell carcinoma subtypes)
What this study cannot tell us
Small patient cohort (n=32); in-vitro T cell stimulation may not reflect in-vivo immunity; mechanistic basis for SCC T cell dysfunction not explored; limited to 12 antigens.
How to read the evidence
Preliminary observational study with small but meaningful sample sizes; findings are hypothesis-generating and inform clinical trial design.
When this study was published
Published in 2020; associated with Phase I clinical trial NCT02470468 for DC-based lung cancer immunotherapy.
The bigger picture
This highlights that tumor immunogenicity is not just about antigen expression — the tumor microenvironment and subtype-specific immune suppression determine whether the immune system can respond to cancer peptides.
Questions still open
- What mechanisms cause weaker T cell responses in squamous cell lung cancer despite higher antigen expression?
- Should immunotherapy strategies differ between adenocarcinoma and squamous cell lung cancer?
- Will the DC-based vaccine perform differently across NSCLC subtypes in the clinical trial?
Common questions
Why do different lung cancer types respond differently to immunotherapy?
How are peptide cancer vaccines designed?
Read the original research
Detection of tumor antigens and tumor-antigen specific T cells in NSCLC patients: Correlation of the quality of T cell responses with NSCLC subtype.
Immunology letters, 219, 46-53
Citation
Palata, Ondrej; Podzimkova Hradilova, Nada; Mysiková, Dagmar; Kutna, Beata; Mrazkova, Hana; Lischke, Robert; Spisek, Radek; Adkins, Irena. (2020). Detection of tumor antigens and tumor-antigen specific T cells in NSCLC patients: Correlation of the quality of T cell responses with NSCLC subtype.. Immunology letters, 219, 46-53. https://doi.org/10.1016/j.imlet.2020.01.001